American Diabetes Association 82nd Scientific Sessions (ADA 2022)

Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.

A once-weekly subcutaneous dose of the GLP-1* receptor agonist dulaglutide successfully controlled glycaemic levels in youths with type 2 diabetes (T2D) being treated with lifestyle modification with or without metformin or insulin, results of the multinational, phase III AWARD-PEDS** study showed.

A novel artificial intelligence platform that integrates multidimensional data to deliver precision nutrition and health recommendations not only helps to induce remission in type 2 diabetes but also to normalize a range of glycaemic and extraglycaemic parameters, as shown in a study presented at the 82nd American Diabetes Association (ADA) Scientific Sessions.

Higher consumption of dairy products is associated with a lower risk of type 2 diabetes (T2D) among US adults, according to a nationally representative study presented at ADA 2022.

Automating insulin delivery with an open-source algorithm that is run on a smartphone proves safe and effective in the management of type 1 diabetes (T1D), as shown in the results of Community Derived Automated Insulin Delivery (CREATE) trial.

Patients with type 2 diabetes (T2D) who lose more weight appear to have better quality of life (QoL), an effect that is independent of treatments received, according to a study presented at the recent 82nd Scientific Sessions by the American Diabetes Association (ADA 2022).

A study of Thai patients with impaired glucose tolerance (IGT) has found only a slight reduction in weight among its participants, highlighting the need for more intensive efforts with structured lifestyle programs to prevent diabetes.